top of page
OcuMedic is Revolutionizing Ocular Drug Delivery utilizing Patented New Platform Technology
-
10 Issued US and worldwide Patents
-
Freedom to Operate Opinion​
-
FDA 505(B)(2) Regulatory Pathway approved
Latest News
Meet us at Ophthalmology Innovation Summit (OIS) XV
November 21-22, 2025
OcuMedic co-Founder and CEO, Keith Ignotz, will discuss exciting developments and future milestones in the conference's "Drug Delivery Showcase."
OcuMedic's Technology
The patented technology was developed by Mark Byrne, Ph. D., Distinguished Professor of Chemical and Biomedical Engineering & Founding Head of the Biomedical Engineering Department/Founding Dean Health Engineering and Science at Rowan University. Dr. Byrne serves as Co-founder of OcuMedic and Chief Technical Officer of the company. The technology rests on 10 issued patents, and a recent Freedom to Operate (FTO) opinion. Efficacy has been proven in animal models.
The technology is based on a novel therapeutic contact lens, made from the most widely used lens material, silicone hydrogel (SiHy), capable of controlled release of first line ophthalmic agents. The platform technology is tested for a use with anti-inflammatory and antibiotic agents, as well as 10 other drugs. It is also an ideal platform for treatment of dry eye especially episodic flairs.
Problem
-
Patient eye drops after cataract and LASIK surgery are inefficient at delivering medication to the targeted tissue
​
-
Treatment plan requires patients to administer multiple drops per day
​
-
Missed dosing could lead to higher health care costs through complications and additional doctor visits
​
Solution
-
OcuMedic FREEDOM™ Lens continuously delivers drug to targeted tissue
-
One lens per week solves compliance issues
​
-
Lower total health care costs through better results and shorter recovery time
​
Market Opportunity
-
Eye drop market is $16B and growing at 8% annually
​
-
Cataract surgeries are increasing due to the aging population (4m/year expected to grow to 6m by 2030)
​
-
Ophthalmologists and Optometrists desire more efficient treatment plans to maximize patient results and reduce recovery times
​
Investment Opportunity
-
Phase I clinical testing in 1Q 2026 will demonstrate performance and advance FDA approval
​
-
New investment round to be opened in 1Q 2026​
bottom of page